RESUMO
The rise of the opioid epidemic and the increasing rate of suicides have drawn attention to mental health and addiction and have highlighted the need for collaboration between public health and behavioral health. However, these 2 fields have had limited engagement with one another. The introduction of Public Health 3.0 and population-based financing models that promote prevention and value in health care have created opportunities and incentives for local health departments and behavioral health agencies and providers to work together. New undertakings include the creation of accountable care organizations, community health needs assessment requirements for all non-profit hospitals, local health department requirements to conduct community Health Assessments (CHA), and increasing numbers of public health departments that are pursing accreditation. We argue that by taking advantage of these opportunities and others, local health departments can play a vital role in addressing critical challenges in mental health and addiction facing their communities.
Assuntos
Acreditação , Comportamento Cooperativo , Saúde Mental , Administração em Saúde Pública/normas , Humanos , Estados UnidosRESUMO
The experience of adversity and toxic stress in childhood is associated with the development of chronic health and behavioral health problems. These problems contribute substantially to health care expenditures and the overall burden of disease. Although a strong scientific literature documents the effectiveness of primary prevention in reducing childhood adversity, promoting well-being and lessening the incidence of negative outcomes, funding for these interventions is highly fragmented across multiple government agencies as well as private and philanthropic sectors. It is becoming increasingly clear that improving population health will require a concentrated public health effort to improve access to and the accountability of these interventions as well as the development of novel financing schemes. In this perspective we review existing financing mechanisms for funding interventions known to reduce adverse childhood experiences and discuss innovative financing approaches that use insurance as well as pay-for-success funding mechanisms. The latter require that cost savings associated with primary prevention be quantified and that these savings be used to offset program costs, sometimes with a return on investment for private investors. We provide a series of recommendations regarding better coordination and strategic oversight of existing resources as well as the need to further develop and validate methodologies for estimating the societal costs and benefits associated with the varying social policies that are designed to ameliorate the effects of adversity and to build resilience.
Assuntos
Financiamento da Assistência à Saúde , Acontecimentos que Mudam a Vida , Prevenção Primária/economia , Saúde Pública/economia , Resiliência Psicológica , Criança , Governo Federal , Financiamento Governamental , Fundações , Política de Saúde , Promoção da Saúde/economia , Humanos , Seguro Saúde , Governo Local , Reembolso de Incentivo , Governo EstadualRESUMO
Before the development of the germ theory in the late 19th century, infectious illnesses were largely uncontrollable and caused significant mortality. Implementing public hygiene, preventive, and treatment interventions created remarkable improvements in population health. Today's U.S. public health crises involve threats to health and human capital evidenced by multiple indicators of deteriorating wellbeing. These problems result from the interaction of risk and protective factors. Specifically, we argue that the interaction of genetic vulnerability and toxic stress are antecedents to a developmental cascade that undermines healthy development and human capital. We review relevant literature, summarize effective strategies to prevent or ameliorate this deterioration, and outline a theory of the mechanisms currently undermining our health. A series of strategies that we believe will constitute the next major era in public health are discussed, involving actions at the individual/family, community and societal level to reduce risk and strengthen protective factors. (PsycINFO Database Record
Assuntos
Interação Gene-Ambiente , Comportamentos Relacionados com a Saúde , Transtornos Mentais/prevenção & controle , Transtornos Mentais/terapia , Saúde Pública/tendências , Estresse Psicológico , Família , Humanos , Metanálise como Assunto , Modelos Teóricos , Características de Residência , Fatores de Risco , Estados UnidosAssuntos
Internação Compulsória de Doente Mental/economia , Serviços Comunitários de Saúde Mental/economia , Transtornos Mentais , Serviço Social em Psiquiatria/economia , Internação Compulsória de Doente Mental/legislação & jurisprudência , Serviços Comunitários de Saúde Mental/legislação & jurisprudência , Humanos , Transtornos Mentais/psicologia , Transtornos Mentais/reabilitação , Transtornos Mentais/terapia , Serviço Social em Psiquiatria/legislação & jurisprudência , Estados UnidosRESUMO
Comparative effectiveness research holds great promise for improving the care of people with mental health conditions and disorders related to substance abuse. But inappropriate application of such research can threaten the quality of that care. We examine the controversy surrounding a large real-world trial of schizophrenia treatments and conclude that the initial presentation of results led to overly simplistic policy suggestions that had the potential to harm patients. Patient advocacy groups helped illuminate these consequences and helped stimulate further discussion and analysis. Researchers must engage stakeholders, especially patients, in all aspects of comparative effectiveness research and translate the findings into sound mental health policy and practice.